AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?

NCT ID NCT06843499

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether an artificial intelligence system called VeriSee can help doctors diagnose age-related macular degeneration and diabetic retinopathy from standard eye photos. The AI analyzes the images and provides instant results for the ophthalmologist to consider. Researchers will measure how accurate the AI is compared to a specialist's diagnosis and whether it saves time and money.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AI-assisted diagnostic software (VeriSee) that analyzes eye photos to screen for age-related macular degeneration, diabetic retinopathy, and glaucoma
What this could lead to
If effective, AI-assisted screening could make eye disease diagnosis faster and more accessible, potentially catching vision-threatening conditions earlier.
What could go wrong
The AI may not match the accuracy of a specialist exam, and false positives or negatives could lead to unnecessary worry or missed diagnoses. The trial is also limited to specific clinics and age groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan, 100225, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.